245 related articles for article (PubMed ID: 29401167)
21. Association of Long-Term, New-Onset, and Postsurgical Diabetes With Survival in Patients With Resectable Pancreatic Cancer: A Retrospective Cohort Study.
Kanbour S; Yenokyan G; Abusamaan M; Laheru D; Alam A; El Asmar ML; Virk Z; Hardenbergh D; Mathioudakis N
Pancreas; 2023 Jul; 52(6):e309-e314. PubMed ID: 37890159
[TBL] [Abstract][Full Text] [Related]
22. Tumour budding in pancreatic cancer revisited: validation of the ITBCC scoring system.
Karamitopoulou E; Wartenberg M; Zlobec I; Cibin S; Worni M; Gloor B; Lugli A
Histopathology; 2018 Jul; 73(1):137-146. PubMed ID: 29495092
[TBL] [Abstract][Full Text] [Related]
23. Preoperative diabetes mellitus and long-term survival after resection of pancreatic adenocarcinoma.
Chu CK; Mazo AE; Goodman M; Egnatashvili V; Sarmiento JM; Staley CA; Galloway JR; Adsay NV; Jacobs S; Kooby DA
Ann Surg Oncol; 2010 Feb; 17(2):502-13. PubMed ID: 19885697
[TBL] [Abstract][Full Text] [Related]
24. Is chronic hepatitis B infection a protective factor for the progression of advanced pancreatic ductal adenocarcinoma? An analysis from a large multicenter cohort study.
Chen Q; Ning Z; Wang L; Ying H; Dong S; Zhang C; Shen X; Guo Y; Chen H; Zhu X; Shen Y; Shi W; Hua Y; Wang K; Lin J; Xu L; Chen L; Feng L; Zhang X; Xie J; Sun B; Sun Y; Gu W; Kang M; Tang Z; Chen Z; Chen Z; Liu L; Yu J; Li Z; Meng Z
Oncotarget; 2016 Dec; 7(51):85603-85612. PubMed ID: 27811354
[TBL] [Abstract][Full Text] [Related]
25. Prior history of acute pancreatitis predicts poor survival in patients with resectable pancreatic ductal adenocarcinoma.
Gong Y; Fan Z; Luo G; Huang Q; Qian Y; Cheng H; Jin K; Ni Q; Yu X; Liu C
Pancreatology; 2020 Jun; 20(4):716-721. PubMed ID: 32249060
[TBL] [Abstract][Full Text] [Related]
26. Prognostic impact of Charlson's Age-Comorbidity Index and other risk factors in patients with pancreatic cancer.
Bagni K; Chen IM; Johansen AZ; Dehlendorff C; Jensen BV; Hansen CP; Preus Hasselby J; Holländer NH; Nissen M; Bjerregaard JK; Pfeiffer P; Yilmaz MK; Rasmussen LS; Nielsen SE; Johansen JS
Eur J Cancer Care (Engl); 2020 May; 29(3):e13219. PubMed ID: 31908093
[TBL] [Abstract][Full Text] [Related]
27. Serum Marker Score Based on Prognostic Nutrition Index, Carcinoembryonic Antigen, and Carbohydrate Antigen 19-9 Is Associated With Recurrence for Patients Undergoing Surgery for Pancreatic Ductal Adenocarcinoma.
Nakagawa S; Yamashita YI; Umezaki N; Yamao T; Okabe H; Imai K; Nitta H; Hashimoto D; Chikamoto A; Baba H
Pancreas; 2018 Oct; 47(9):1130-1134. PubMed ID: 30161074
[TBL] [Abstract][Full Text] [Related]
28. Metformin Improves Survival in Patients with Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: A Propensity Score Analysis.
Amin S; Mhango G; Lin J; Aronson A; Wisnivesky J; Boffetta P; Lucas AL
Am J Gastroenterol; 2016 Sep; 111(9):1350-7. PubMed ID: 27430290
[TBL] [Abstract][Full Text] [Related]
29. Systemic Inflammatory Response and Elevated Tumour Markers Predict Worse Survival in Resectable Pancreatic Ductal Adenocarcinoma.
Salmiheimo A; Mustonen H; Stenman UH; Puolakkainen P; Kemppainen E; Seppänen H; Haglund C
PLoS One; 2016; 11(9):e0163064. PubMed ID: 27632196
[TBL] [Abstract][Full Text] [Related]
30. Fasting Blood Glucose Levels Provide Estimate of Duration and Progression of Pancreatic Cancer Before Diagnosis.
Sharma A; Smyrk TC; Levy MJ; Topazian MA; Chari ST
Gastroenterology; 2018 Aug; 155(2):490-500.e2. PubMed ID: 29723506
[TBL] [Abstract][Full Text] [Related]
31. Prognostic significance of growth factors and the urokinase-type plasminogen activator system in pancreatic ductal adenocarcinoma.
Xue A; Scarlett CJ; Jackson CJ; Allen BJ; Smith RC
Pancreas; 2008 Mar; 36(2):160-7. PubMed ID: 18376307
[TBL] [Abstract][Full Text] [Related]
32. The Significance of Ascites in Patients With Pancreatic Ductal Adenocarcinoma: A Case-Control Study.
Baretti M; Pulluri B; Tsai HL; Blackford AL; Wolfgang CL; Laheru D; Zheng L; Herman J; Le DT; Narang AK; de Jesus-Acosta A
Pancreas; 2019 Apr; 48(4):585-589. PubMed ID: 30817723
[TBL] [Abstract][Full Text] [Related]
33. Metformin Use and Pancreatic Cancer Survival among Non-Hispanic White and African American U.S. Veterans with Diabetes Mellitus.
Toriola AT; Luo S; Thomas TS; Drake BF; Chang SH; Sanfilippo KM; Carson KR
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):169-175. PubMed ID: 31685560
[TBL] [Abstract][Full Text] [Related]
34. Resectable invasive IPMN versus sporadic pancreatic adenocarcinoma of the head of the pancreas: Should these two different diseases receive the same treatment? A matched comparison study of the French Surgical Association (AFC).
Duconseil P; Périnel J; Autret A; Adham M; Sauvanet A; Chiche L; Mabrut JY; Tuech JJ; Mariette C; Régenet N; Fabre JM; Bachellier P; Delpéro JR; Paye F; Turrini O
Eur J Surg Oncol; 2017 Sep; 43(9):1704-1710. PubMed ID: 28687431
[TBL] [Abstract][Full Text] [Related]
35. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
[TBL] [Abstract][Full Text] [Related]
36. PROX1 and β-catenin are prognostic markers in pancreatic ductal adenocarcinoma.
Saukkonen K; Hagström J; Mustonen H; Juuti A; Nordling S; Kallio P; Alitalo K; Seppänen H; Haglund C
BMC Cancer; 2016 Jul; 16():472. PubMed ID: 27411302
[TBL] [Abstract][Full Text] [Related]
37. Preoperative independent prognostic factors in patients with borderline resectable pancreatic ductal adenocarcinoma following curative resection: the neutrophil-lymphocyte and platelet-lymphocyte ratios.
Asari S; Matsumoto I; Toyama H; Shinzeki M; Goto T; Ishida J; Ajiki T; Fukumoto T; Ku Y
Surg Today; 2016 May; 46(5):583-92. PubMed ID: 26108488
[TBL] [Abstract][Full Text] [Related]
38. Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma.
Ben Q; An W; Wang L; Wang W; Yu L; Yuan Y
Pancreas; 2015 Apr; 44(3):471-7. PubMed ID: 25423560
[TBL] [Abstract][Full Text] [Related]
39. Low RASSF6 expression in pancreatic ductal adenocarcinoma is associated with poor survival.
Ye HL; Li DD; Lin Q; Zhou Y; Zhou QB; Zeng B; Fu ZQ; Gao WC; Liu YM; Chen RW; Li ZH; Chen RF
World J Gastroenterol; 2015 Jun; 21(21):6621-30. PubMed ID: 26074700
[TBL] [Abstract][Full Text] [Related]
40. Update on the management of pancreatic cancer: surgery is not enough.
Ansari D; Gustafsson A; Andersson R
World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
